

WORLD ADVANCED THERAPIES & REGENERATIVE MEDICINE CONGRESS 2017

17-19 May 2017, Business Design Centre, London

Last year the 12th World Stem Cells & Regenerative Medicine Congress brought together over 600 attendees from industry, healthcare, research, investment and biotech from around the world to discuss the latest ground-breaking scientific discoveries, therapeutic breakthroughs, cell and gene therapies and regenerative medicine. It was held at the Business Design Centre in London, together with the 2nd annual Cord Blood World Europe Congress and the inaugural World Precision Medicine Congress.

The highlights included presentations from: George Freeman (Minister for Life Sciences, UK Parliament), Sven Kili (VP & Head of Gene Therapy Development, GSK), Paula Salmikangas (CAT chair, EMA), Bruce Levine (Professor of Cancer Gene Therapy, UPenn), Margo Roberts (CSO, Kite) and James Nobel (CEO, Adaptimmune); along with world-class speaker faculty of over 180 speakers from the world's leading pharma, biotech, and academic institutions, a full exhibition floor featuring the most advanced technologies in this sector.

In May 2017 the newly named World Advanced Therapies & Regenerative Medicine Congress, will bring together 800+ attendees and explore the rapidly developing world of ATMPs (Advanced Therapy Medicinal Products). From process development to clinical translation this congress will bring you the most exciting case studies and new data. Experts in every area will help you tackle the process and regulatory hurdles of developing these new therapeutic formats all the way through manufacture and into the clinic.

Taking place alongside the co-located 2nd annual World Precision Medicine Congress and 3rd annual Cord Blood World Europe, and hosting 250+ speakers, 4 tracks of content across the 3 days enabling networking opportunities with over 800 leading industry professionals.

We look forward to welcoming you to London on 17th – 19th May.

Early confirmed speakers include:

Keynotes:

William (Bill) Burns, Governor and Trustee for Wellcome Trust, Vice Chairman, Vestergaard, Trustee for the Institute of Cancer Research, London, Vice Chairman, Mesoblast and Scientific Advisory Board Member for the University of Cologne/Bonn Center for Integrated Oncology

Susan Solomon, CEO and Co-Founder, New York Stem Cell Foundation

Joanne Kurtzberg, Director, Carolinas Cord Blood Bank, Duke University

Speakers:

Alain Vertes, Managing Director, NxR Biotechnologies

Anthony Lodge, ATMPs Regulatory Affairs Manager, Chiesi Group

Barry Rosen, Senior Principal Scientist/Director, AstraZeneca

Bo Kara, Head Process Development, Cell & Gene Therapy Platform CMC, GSK

Claudia Mitchell, CEO, Universal Cells Inc.

Damien Bates, Chief Medical Officer & Head of Research, SanBio

David Pettitt, Research Associate, Centre for the Advancement of Sustainable

Medical Innovation (CASMI), Medical Sciences, University of Oxford

Didier Caizergues, Head of Regulatory Affairs Department, Généthron

Eduardo Bravo, CEO, TiGenix

Elisa Manzotti, CEO, BioInsights Publishing Ltd

Gil Van Bokkelen, CEO, Athersys Inc.

Greg Bonfiglio, Founder & Managing Partner, Proteus Venture Partners

Helen Tayton Martin, COO, Adaptimmune

James Noble, CEO, Adaptimmune

Jane Lebkowski, President of R&D, Asterias Biotherapeutics

Jaroslav Michalek, CEO, Cellthera; President, International Consortium for Cell Therapy and Immunotherapy

Jeff Abbey, CEO, Argos Therapeutics

John Campbell, Associate Director, Research, Development & Innovation

SNBTS, National Science Laboratory

John Maher, CSO, Leucid Bio

John Tchelingirian, CEO, Promethera Biosciences

Katy Spink, Chief Operating Officer, Asterias Biotherapeutics

Kevin Docherty, MacLeod Smith Professor of Biochemistry, University of Aberdeen, School of Medical Sciences

Kristin Comella, Chief Science Officer, US Stem Cell Inc.

Kunihiko Suzuki, Vice Chairman, Member of the Board, MEDINET Co., Ltd.

Marcie Glicksman, CSO, Orig3n

Mark Zimmerman, Vice President, Business Development and Strategy, ViaCyte

Michael West, CEO, BioTime

Nick Crabb, Programme Director – Scientific Affairs, NICE

Norio Nakatsuji, Professor Emeritus, Kyoto University & Chief Advisor, Stem Cell & Device Laboratory, Inc.

Oren Levy, Instructor of Medicine, Harvard Medical School/Brigham and Women's Hospital

Patrick Ginty, Manager CMC Biopharm, GSK

Scott Thies, Director of Operations, Heart Regeneration Program, University of Washington

Silviu Itescu, CEO, Mesoblast

Sven Kili, Vice President & Head, Gene Therapy Development, GSK

Tony Simula, Program Manager, R&D at CRC for Cell Therapy Manufacturing - CRC for Cell Therapy Manufacturing

Václav Procházka, Deputy director for Science & Research, University Hospital Ostrava

Yen Choo, CEO, Progenitor Therapeutics

Zami Aberman, Chairman & CEO, Pluristem Therapeutics

Our Scientific Advisory Board 2017

Ajan Reginald, CEO, Cell Therapy Limited (CTL)
Charles Craddock, Chairman, UK Stem Cell Strategic Oversight Committee,
NHS Blood and Transplant
Claudia Mitchell, CEO, Universal Cells Inc.
Eduardo Bravo, Managing Director and CEO, TiGenix
Edward Lanphier, President & CEO, Sangamo Biosciences
Enrico Bastianelli, CEO, Bone Therapeutics
Ian Massey, President & CEO, StemCells, Inc.
John Tchelingierian, CEO, Promethera, Biosciences
Katy Spink, Chief Operating Officer, Asterias Biotherapeutics
Kristin Comella, Chief Science Officer, US Stem Cell Inc.
Michael Leek, Chief Executive, TC BioPharm
Nick Crabb, Programme Director – Scientific Affairs, NICE
Sven Kili, Vice President & Head, Gene Therapy Development, GSK
Zami Aberman, Chairman & CEO, Pluristem Therapeutics

**PLEASE NOTE THIS AGENDA IS A DRAFT AND IS NOT FOR DISTRIBUTION, SPEAKERS ARE IN THE PROCESS
OF BEING INVITED UNLESS STATED AS 'CONFIRMED'**

2017 Sponsors & Exhibitors Include

2017 SPONSORS & EXHIBITORS INCLUDE			
Gold Sponsor 	Platinum Sponsor 	Silver Sponsor 	Associate Sponsor 
Exhibitor 	Exhibitor 	Exhibitor 	Exhibitor 
Exhibitor 	Exhibitor 	Exhibitor 	

PLEASE NOTE THIS AGENDA IS A DRAFT AND IS NOT FOR DISTRIBUTION, SPEAKERS ARE IN THE PROCESS OF BEING INVITED UNLESS STATED AS 'CONFIRMED'

Agenda at a Glance:

				Day 1			
World Advanced Therapies & Regenerative Medicine Congress				World Precision Medicine Congress		Cord Blood World Europe	
THE CELL & GENE DIRECTOR FORUM	PROCESS DEVELOPMENT & MANUFACTURING	SHOWCASE SYMPOSIUM	STEM CELLS IN REGEN MED	Data & services	Clinical Programmes		
AM	Plenary Keynote			Plenary Keynote		Keynote	
AM	Regulation & Reimbursement	Process development: Scale up and scale out	Clinical Showcases	Starting materials, isolation & selection of target cells, cell culture, activation and stimulation	Big data, patient cohorts, data security	Rare Disease	Future of blood banks
PM							
PM							
Day 2							
World Advanced Therapies & Regenerative Medicine Congress				World Precision Medicine Congress		Cord Blood World Europe	
THE CELL & GENE DIRECTOR FORUM	PROCESS DEVELOPMENT & MANUFACTURING	SHOWCASE SYMPOSIUM	STEM CELLS IN REGEN MED	Diagnostics & e-health	Clinical Programmes		
AM	Investment & funding strategies	GMP Manufacturing & formulation of finished product	Cell Therapy Showcases	Stem cells as a research tool	Dx, pharma CDx development, biomarkers, e-health and connectivity	Oncology	Novel treatments to improve future usages
AM				Stem cell transplantations			
PM							
PM							
Day 3							
World Advanced Therapies & Regenerative Medicine Congress				World Precision Medicine Congress		Cord Blood World Europe	
THE CELL & GENE DIRECTOR FORUM	SUPPLY CHAIN MANAGEMENT	SHOWCASE SYMPOSIUM	STEM CELLS IN REGEN MED	Infrastructure and investment	Clinical Programmes		
AM	Clinical development and product release	Cryopreservation & labelling	Gene Therapy Showcases	Tissue engineering and organ regeneration	Cluster development, incubator/accelerator facilities, funding	Infectious Diseases and Other Complex Conditions	See Supply Chain Management session as part of World Advanced Therapies & Regenerative Medicine Congress
AM		Cell banking & repositories					
PM		Logistics, Transport & Shipping					

Agenda at a Glance:

	Day 1							
	World Advanced Therapies & Regenerative Medicine Congress				World Precision Medicine Congress		Cord Blood World Europe	
	THE CELL & GENE DIRECTOR FORUM	PROCESS DEVELOPMENT & MANUFACTURING	SHOWCASE SYMPOSIUM	STEM CELLS IN REGEN MED	Data & services	Clinical Programmes		
AM	Plenary Keynote				Plenary Keynote		Keynote	
AM	Regulation & Reimbursement	Process development: Scale up and scale out	Clinical Showcases	Starting materials, isolation & selection of target cells, cell culture, activation and stimulation	Big data, patient cohorts, data security	Rare Disease	Future of blood banks	
PM								
PM								
	Day 2							
	World Advanced Therapies & Regenerative Medicine Congress				World Precision Medicine Congress		Cord Blood World Europe	
	THE CELL & GENE DIRECTOR FORUM	PROCESS DEVELOPMENT & MANUFACTURING	SHOWCASE SYMPOSIUM	STEM CELLS IN REGEN MED	Diagnostics & e-health	Clinical Programmes		
AM	Investment & funding strategies	GMP Manufacturing & formulation of finished product	Cell Therapy Showcases	Stem cells as a research tool	Dx, pharma CDx development, biomarkers, e-health and connectivity	Oncology	Novel treatments to improve future usages	
AM				Stem cell transplantations				
PM								
PM								
	Day 3							
	World Advanced Therapies & Regenerative Medicine Congress				World Precision Medicine Congress		Cord Blood World Europe	
	THE CELL & GENE DIRECTOR FORUM	SUPPLY CHAIN MANAGEMENT	SHOWCASE SYMPOSIUM	STEM CELLS IN REGEN MED	Infrastructure and investment	Clinical Programmes		
AM	Clinical development and product release	Cryopreservation & labelling	Gene Therapy Showcases	Tissue engineering and organ regeneration	Cluster development, incubator/accelerator facilities, funding	Infectious Diseases and Other Complex Conditions	See Supply Chain Management session as part of World Advanced Therapies & Regenerative Medicine Congress	
AM		Cell banking & repositories						
PM		Logistics, Transport & Shipping						

2017's Advanced Therapies and Regenerative Medicine Programme Agenda Overview:

World Advanced Therapies and Regenerative Medicine Day 1				
	Plenary – The Next Generation of Advanced Therapies			
08:30	Keynote Presentation: William (Bill) Burns , Governor and Trustee, Wellcome Trust ; Vice Chairman, Vestergaard ; Trustee for the Institute of Cancer Research, London, and Scientific Advisory Board Member, University of Cologne/Bonn Center for Integrated Oncology (confirmed)			
	<i>One-on-one interviews with some of cell and gene therapies' principal thought-leaders from across the globe, discussing what they are doing to push cell and gene based therapies forward to help patients.</i>			
09:00	CRISPR and engineered cells: how have new gene editing techniques changed the face of cell and gene therapy?			
09:25	Process development and GMP for cell and gene therapies in 2017			
09:50	Combination therapy: an update on clinical trial design and translation			
10:15	Presentation by Thermo Fisher Scientific			
10:35	Networking refreshment break			
11:30	Plenary Round Table Discussion Session: Process Development & Manufacturing Focus			
	CAR-T & combination therapy: clinical translation & manufacturing	Optimisation of CRISPR, viral vectors & vaccines: what works and how to move forward	Adopting new closed manufacturing systems for cell therapy	Working with a CMO: GMP for MSCs with clinical applications
	Innate immunotherapy (NK/NKT/CIK etc) cells and cell therapy	Advances in allogenic stem cell therapy, MSCs and pluripotent cells	Tackling quality characterization and the competition with hospital exemption procedures nationally	Quality control, process improvement, and validation projects
12:35	Speed Networking A fun, exciting and effective way to make a lot of initial connections (in a very different environment from the standard business networking meetings).			
13:00	Networking Lunch			

14:30	Cell & Gene Therapy Directors Forum	Product, process & manufacturing development of ATMPs	Clinical development of Immunotherapy & cell therapy	New Techniques for clinical translation of ATMPs
	Regulation, Reimbursement & Commercialisation of Advanced Therapies around the Globe	New paradigms in manufacture: gene therapy and viral vectors	Developments in clinical trials and translations	Stem cell and regen med case studies in the clinic
	How are different markets approaching the regulation and commercialisation of advanced therapies?	Yield, safety & quality of gene therapy and viral vectors	Manufacture and clinical development of CAR-T cell therapy	Case Studies: Oncology
	Pricing and reimbursement beyond approval: a panel of payers and analysts	Transitioning to new closed systems, lessons learned from big pharma	Clinical development of MSCs for chronic neurological deficits – the SanBio experience	Case Studies Cardiology
	Spinning out from academia to small start-up & beyond	Tackling the bottleneck in advanced therapy process development	A paradigm shift in cell therapy: current data on how product effects clinical outcomes	Case Studies: Neurological
	Scaling up to phase 2 & 3 trials: lessons learned	Scaling up & scaling out best practice case studies	How do you conduct a 'good' clinical trial with cell therapies and autologous transplants?	Case Studies: Musculoskeletal & Osteoarthritis
	Ensuring clinical translation & market access	GMP, logistics and supply chain management for cell and gene therapy	Advances in cell therapy (T-Cells, NK Cells, DCs, Vaccines, iPSCs & MSCs)	Case studies: Hepatic and retinal
18:00	End of Day 1 – External Network			

World Advanced Therapies and Regenerative Medicine Day 2				
	Inspirational stories from around the world			
09:00	Learning from other successful industries: how can we ensure clinical success of cell and gene therapies?			
09:25	Why are ATMPs so important? Patients give their view			
09:50	Missions to change cancer: hear from charities and projects making a difference			
10:15	Reserved for supporting partner			
10:35	Networking refreshment break			
11:35	Breakout Sessions Day 2			
	Cell & Gene Therapy Directors Forum	Product, process & manufacturing development	CRISPR & Gene Editing	Advances in therapeutic technologies
	Regulation, Reimbursement & Commercialisation of Advanced Therapies around the Globe	GMP, logistics and supply chain management for cell and gene therapy	Using CRISPR to control disease in humans	New Frontiers in repair and replacement of diseased tissues and organs
	Overcoming the challenges of rolling out advanced therapies in Europe	Process is product: cell selection, indication and administration	Translating CRISPR/Cas9 technology into breakthrough human therapeutics in a number of serious diseases	Developing a closed loop design and manufacturing framework for medical devices
	Japanese accelerated pathway: case studies	GMP manufacturing & standardisation of bioprocess development	Genetics and regenerative medicine	Engineering solutions to regenerative medicine challenges
	Evolving European & US paradigms (REGROW)	Supply, logistics, transport & shipping	Pluripotent and reprogrammed cells for regenerative medicine	New frontiers in repair and replacement of diseased tissues and organs
	Case studies of regulatory approval of late stage cell therapy products			
	Discussion session on stem cell regulation in Japan and Asia	Formulation of finished product	Practical challenges of using gene editing technologies; Scaling up & regulation	3D bioprinting strategies
	Q&A session with regulatory bodies	Cryopreservation & cell banking	Clinical development and commercialization of one-time potentially curative therapies	Development of new technologies for organ replacement using regenerative medicine approaches (bioengineering, cell transplantation, and organ engineering) to generating entire replacement organs

17:00	<i>Afternoon Keynote presentations and panel discussion shared with Precision Medicine World Congress:</i> Susan Solomon , CEO and Co-Founder, New York Stem Cell Foundation (confirmed) Joanne Kurtzberg , Director, Carolinas Cord Blood Bank, Duke University (confirmed)
17:30	Evening plenary on Bioelectronic Medicine
18:00	Poster Viewing and Networking Reception
	End of day 2

08:00	World Advanced Therapies and Regenerative Medicine Day 3		
	Cell therapy discovery and applications	Regenerative Medicine	New Research Showcase
	Product Research & Development	A new era of Regenerative Medicine	Quick fire updates on techniques and technologies for cell and gene therapy research and development
	The Immuno-oncology revolution: how close are we?	Pluripotent and reprogrammed cells for regenerative medicine: what we know now	Oncology
	Targeting regulatory T cells for cancer immunotherapy	Recent Advances in clinical approaches to therapies	Neurological
	Mechanism-based combination strategies in cancer immunotherapy	New frontiers in repair and replacement of diseased tissues and organs	Musculoskeletal
	Stem cells as a tool for drug discovery	Addressing uncertainty in regenerative medicine	Rare diseases
	Using stem cells models to understand effects of gene and environment on disease	Cell culture, activation & stimulation	Cardiovascular
	Closing keynote: What's next for advanced therapies? Predicted directions for immune therapy based on current data.		
15:30	End of Day 3		